Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)
Historic EBT Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 145.57%.
- Amylyx Pharmaceuticals' EBT Margin fell 1506800.0% to 145.57% in Q4 2024 from the same period last year, while for Sep 2025 it was 571.57%, marking a year-over-year decrease of 4527500.0%. This contributed to the annual value of 264.42% for FY2024, which is 2770000.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported EBT Margin of 145.57% as of Q4 2024, which was down 1506800.0% from 17476.92% recorded in Q3 2024.
- Amylyx Pharmaceuticals' EBT Margin's 5-year high stood at 22.15% during Q2 2023, with a 5-year trough of 17476.92% in Q3 2024.
- Moreover, its 4-year median value for EBT Margin was 145.57% (2024), whereas its average is 3904.26%.
- In the last 5 years, Amylyx Pharmaceuticals' EBT Margin soared by 98703100bps in 2023 and then tumbled by -174969600bps in 2024.
- Amylyx Pharmaceuticals' EBT Margin (Quarter) stood at 8120.0% in 2021, then soared by 98bps to 162.77% in 2022, then soared by 103bps to 5.11% in 2023, then plummeted by -2946bps to 145.57% in 2024.
- Its EBT Margin was 145.57% in Q4 2024, compared to 17476.92% in Q3 2024 and 7106.55% in Q2 2024.